Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its Q2 2025 financial results announcement for August 6, 2025 after market close.

The company will host a conference call at 2:00 PM PT (5:00 PM ET) on the same day, featuring Chair and CEO Leslie Trigg and CFO Renee Gaeta. Participants can register online to receive dial-in details, and a webcast will be available on the company's investor relations website.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.outsetmedical.com.

Outset Medical has appointed Renee Gaeta as its new Chief Financial Officer, effective immediately. Gaeta, who will oversee Finance, IT, and HR, succeeds Nabeel Ahmed. She previously served as CFO at Shockwave Medical until its $13B acquisition by Johnson & Johnson in 2024, and held CFO positions at Eko Health and Establishment Labs. The company reaffirmed its 2025 financial guidance, projecting revenue between $115M-$125M and non-GAAP gross margin in the high-30% range. Gaeta brings significant experience from publicly traded medical device companies, both as CFO and board member, including roles at Candel Therapeutics and SeaSpine Holdings. Outset Medical, a medical technology company, focuses on reducing dialysis cost and complexity through its Tablo technology.

Outset Medical (Nasdaq: OM) has appointed healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee, replacing Dale E. Jones who has stepped down. O'Boyle brings over 20 years of healthcare leadership experience, having served as CFO of several public companies and as a board director for 6 public medical device companies.

O'Boyle's extensive board experience includes positions at Nevro Corp., GenMark Diagnostics (as Chairman), Sientra, Wright Medical Group, Zeltiq Aesthetics, and Durata Therapeutics. He previously served as CFO of Advanced Biohealing and NuVasive, and currently serves on the board of Carlsmed, a private spine surgery solutions company.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its upcoming participation in the RBC Capital Markets Global Health Care conference. The company's management team will present on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.outsetmedical.com.

Outset Medical (Nasdaq: OM) reported strong Q1 2025 financial results with net revenue of $29.8 million, up 6% year-over-year. Key highlights include:

• Tablo console revenue grew 23% from Q4
• Recurring revenue from consumables and services increased 20% to $22.7 million
• Gross margin expanded to 37.2% (37.6% non-GAAP)
• Operating expenses decreased 39% to $27.5 million
• Net loss improved to $25.8 million ($3.66 per share)
• Cash position of $192 million as of March 31, 2025

The company shipped its 3 millionth Tablo treatment and maintained its 2025 revenue guidance of $115-125 million. Management expects to use less than $50 million cash in 2025, down from $103 million in 2024, showing progress toward profitability.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis technology, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025, after market close.

The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day, featuring Chair and CEO Leslie Trigg and CFO Nabeel Ahmed to discuss the financial and operating results. Interested participants can register online to receive dial-in details and a unique pin for the call.

A live and archived webcast will be available on the company's investor relations website.

Outset Medical (Nasdaq: OM) has announced a one-for-fifteen reverse stock split effective March 20, 2025. The medical technology company's common stock will continue trading under the OM symbol on Nasdaq with a new CUSIP number 690145206.

The reverse split, approved by stockholders on March 5, 2025, will reduce outstanding shares from approximately 265 million to 17 million. The split will not alter stockholders' ownership percentages, except for fractional shares which will be paid in cash. The number of authorized shares and par value per share remain unchanged.

The split will proportionally affect shares available under equity incentive plans, stock options, warrants, and restricted stock units. Equiniti Trust Company will manage the process, with registered stockholders' shares automatically converted to book-entry form. Stockholders with shares in 'street name' will have positions automatically adjusted through their brokers.

Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through cost and complexity reduction, has announced its participation in the 45th annual TD Cowen Health Care Conference. The company's management team is scheduled to present on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time.

Interested parties can access both live and archived versions of the presentation through the company's investor relations website at investors.outsetmedical.com. This presentation represents an opportunity for investors and stakeholders to gain insights into Outset Medical's innovative dialysis technology and business strategies.